Related Experiment Video
Updated: Aug 11, 2026
Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
Physiology of monoclonal antibody accretion by tumors
Abstract:
During the past 8 years numerous patients have been injected with radiolabeled monoclonal antibodies for both the diagnosis and treatment of cancer. In general the results, while somewhat promising, have failed to fulfill initial expectations. It is now clear that there are many physiologic barriers that antibodies face in their trek toward their tumor-binding site. Use of terms such as antibody-guided delivery or antibody-guided targeting do not take into account the fact that the antibodies are subject to the same physiologic rules as drugs and hormones. Antibodies are no more 'guided' than any drug or hormone. They reach their binding site via the same delivery mechanisms and accumulate in proportion to their 'receptor's' (antigen's) density. Our knowledge and understanding of the physiologic barriers to the uptake of tumor-associated monoclonal antibodies is limited. To date very few studies have been reported that shed light on this problem. For radiolabeled monoclonal antibodies to fulfill their promise, a greater understanding of these physiologic barriers is needed in order to devise ways in which they may be overcome.
Insights
Radiolabeled monoclonal antibodies show promise for cancer diagnosis and treatment but face physiological barriers. Overcoming these challenges requires a deeper understanding of antibody delivery and tumor uptake mechanisms.
Area of Science:
- Oncology
- Immunology
- Radiopharmaceuticals
Background:
- Radiolabeled monoclonal antibodies (mAbs) have been used for cancer diagnosis and treatment for eight years.
- Despite initial promise, clinical results have not fully met expectations due to unaddressed physiological barriers.
Purpose of the Study:
- To highlight the limited understanding of physiological barriers affecting tumor-associated monoclonal antibody uptake.
- To emphasize the need for further research into these barriers for improved cancer therapies.
Main Methods:
- Review of existing literature on antibody delivery and tumor targeting.
- Analysis of physiological factors influencing monoclonal antibody pharmacokinetics and biodistribution.
Main Results:
- Monoclonal antibodies are subject to physiological rules similar to drugs and hormones, not 'guided' to tumors.
- Antibody accumulation at the tumor site is proportional to antigen density.
- Current knowledge of physiological barriers to monoclonal antibody uptake is insufficient.
Conclusions:
- Enhanced understanding of physiological barriers is crucial for realizing the full potential of radiolabeled monoclonal antibodies.
- Future research should focus on overcoming these barriers to improve cancer targeting and treatment efficacy.
More Related Videos
Related Concept Videos
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
01:31Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
01:26Antibody Actions
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...